Theranexus SA - Asset Resilience Ratio
Theranexus SA (ALTHX) has an Asset Resilience Ratio of 66.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Theranexus SA short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Theranexus SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Theranexus SA total assets.
Liquid Assets Composition Over Time
This chart breaks down Theranexus SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Theranexus SA (ALTHX) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.02 Million | 66.61% |
| Total Liquid Assets | €7.02 Million | 66.61% |
Asset Resilience Insights
- Very High Liquidity: Theranexus SA maintains exceptional liquid asset reserves at 66.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Theranexus SA Industry Peers by Asset Resilience Ratio
Compare Theranexus SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Theranexus SA (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Theranexus SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.61% | €7.02 Million ≈ $8.21 Million |
€10.54 Million ≈ $12.33 Million |
+53.12pp |
| 2024-12-31 | 13.49% | €504.56K ≈ $589.88K |
€3.74 Million ≈ $4.37 Million |
-69.47pp |
| 2021-12-31 | 82.97% | €14.01 Million ≈ $16.38 Million |
€16.89 Million ≈ $19.75 Million |
+54.34pp |
| 2020-12-31 | 28.63% | €5.00 Million ≈ $5.85 Million |
€17.47 Million ≈ $20.42 Million |
-49.79pp |
| 2019-12-31 | 78.42% | €12.05 Million ≈ $14.09 Million |
€15.37 Million ≈ $17.97 Million |
-6.65pp |
| 2018-12-31 | 85.07% | €16.03 Million ≈ $18.75 Million |
€18.85 Million ≈ $22.04 Million |
+72.96pp |
| 2016-12-31 | 12.11% | €348.87K ≈ $407.86K |
€2.88 Million ≈ $3.37 Million |
-39.08pp |
| 2015-12-31 | 51.19% | €1.40 Million ≈ $1.63 Million |
€2.73 Million ≈ $3.19 Million |
-- |
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more